| __timestamp | Gilead Sciences, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 1499100000 |
| Thursday, January 1, 2015 | 3426000000 | 1923500000 |
| Friday, January 1, 2016 | 3398000000 | 2351400000 |
| Sunday, January 1, 2017 | 3878000000 | 2564000000 |
| Monday, January 1, 2018 | 4056000000 | 2397300000 |
| Tuesday, January 1, 2019 | 4381000000 | 2503400000 |
| Wednesday, January 1, 2020 | 5151000000 | 3344600000 |
| Friday, January 1, 2021 | 5246000000 | 4529200000 |
| Saturday, January 1, 2022 | 5673000000 | 4179100000 |
| Sunday, January 1, 2023 | 6090000000 | 4650100000 |
| Monday, January 1, 2024 | 6091000000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Gilead Sciences, Inc. and Viatris Inc. have been at the forefront of this challenge since 2014. Over the past decade, Gilead has seen a steady increase in SG&A expenses, peaking at approximately $6.1 billion in 2023, a 104% rise from 2014. Meanwhile, Viatris has also experienced growth, with expenses reaching around $4.65 billion in 2023, marking a 210% increase from 2014.
Despite Gilead's higher absolute expenses, Viatris's rapid growth in SG&A costs suggests a more aggressive expansion strategy. This data provides a fascinating insight into how these companies balance cost management with growth ambitions. As the industry evolves, the ability to optimize these expenses will remain a key differentiator in maintaining competitive advantage.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.